Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) Overview | 10 | 1 |
| Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) Comparative Analysis | 11 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Development by Companies | 12 | 2 |
| Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Pipeline Products Glance | 15 | 2 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Products under Development by Companies | 17 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Products under Investigation by Universities/Institutes | 18 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Companies Involved in Therapeutics Development | 19 | 18 |
| Acceleron Pharma, Inc. | 19 | 1 |
| AstraZeneca Plc | 20 | 1 |
| AVEO Pharmaceuticals, Inc. | 21 | 1 |
| Celgene Corporation | 22 | 1 |
| Eisai Co., Ltd. | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| F. Hoffmann-La Roche Ltd. | 25 | 1 |
| HanAll Biopharma Co., Ltd. | 26 | 1 |
| Johnson &Johnson | 27 | 1 |
| Millennium Pharmaceuticals Inc | 28 | 1 |
| Mirna Therapeutics, Inc. | 29 | 1 |
| Molecular Partners AG | 30 | 1 |
| MolMed S.p.A. | 31 | 1 |
| Novartis AG | 32 | 1 |
| OncoMed Pharmaceuticals, Inc. | 33 | 1 |
| Pfizer Inc. | 34 | 1 |
| PharmAbcine, Inc. | 35 | 1 |
| Verlyx Pharma Inc. | 36 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Assessment | 37 | 11 |
| Assessment by Monotherapy Products | 37 | 1 |
| Assessment by Target | 38 | 3 |
| Assessment by Mechanism of Action | 41 | 3 |
| Assessment by Route of Administration | 44 | 2 |
| Assessment by Molecule Type | 46 | 2 |
| Drug Profiles | 48 | 79 |
| AV-203 Drug Profile | 48 | 3 |
| AZD-9150 Drug Profile | 51 | 3 |
| CC-122 Drug Profile | 54 | 2 |
| Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma Drug Profile | 56 | 1 |
| codrituzumab Drug Profile | 57 | 1 |
| crizotinib Drug Profile | 58 | 7 |
| dalantercept Drug Profile | 65 | 4 |
| emibetuzumab Drug Profile | 69 | 2 |
| erdafitinib Drug Profile | 71 | 2 |
| golvatinib tartrate Drug Profile | 73 | 2 |
| HL-143 Drug Profile | 75 | 1 |
| ipafricept Drug Profile | 76 | 4 |
| LY-3039478 Drug Profile | 80 | 1 |
| LY-3127804 Drug Profile | 81 | 1 |
| MP-0250 Drug Profile | 82 | 1 |
| MRX-34 Drug Profile | 83 | 6 |
| NGR-hTNF Drug Profile | 89 | 6 |
| OSU-2S Drug Profile | 95 | 1 |
| palbociclib Drug Profile | 96 | 10 |
| pasireotide Drug Profile | 106 | 4 |
| pentamidine isethionate Drug Profile | 110 | 2 |
| PF-04518600 Drug Profile | 112 | 1 |
| PTX-9908 Drug Profile | 113 | 1 |
| sapanisertib Drug Profile | 114 | 3 |
| sonidegib phosphate Drug Profile | 117 | 5 |
| temsirolimus Drug Profile | 122 | 2 |
| TTAC-0001 Drug Profile | 124 | 1 |
| utomilumab Drug Profile | 125 | 2 |
| Metastatic Hepatocellular Carcinoma (HCC) Dormant Projects | 127 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Discontinued Products | 128 | 1 |
| Metastatic Hepatocellular Carcinoma (HCC) Product Development Milestones | 129 | 1 |
| Featured News &Press Releases | 129 | 1 |
| Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio | 129 | 1 |
| May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 | 129 | 1 |
| Appendix | 130 | 2 |
| Methodology | 130 | 1 |
| Coverage | 130 | 1 |
| Secondary Research | 130 | 1 |
| Primary Research | 130 | 1 |
| Expert Panel Validation | 130 | 1 |
| Contact Us | 130 | 1 |
| Disclaimer | 131 | 1 |